Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs Nvidia Corp (NVDA) Price & Performance

Eli Lilly And CoTrade
Nvidia CorpTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Nvidia Corp — how do they compare? Eli Lilly And Co trades at $1,223.44 (market cap $1.08T), while Nvidia Corp trades at $223.35 (market cap $5.27T). The key difference: Nvidia Corp is far larger — about 4.9× Eli Lilly And Co's market cap, and Eli Lilly And Co pays the higher dividend (0.57%). Which is the better fit depends on your goals.

LLYNVDA
Market Cap
$1.08T$5.27T
Sector
HealthTechnology
52-Week High
$1.24K$235.75
52-Week Low
$639.43$165.17
Enterprise Value
$1.13T$5.20T
Dividend Yield
0.57%0.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Nvidia Corp

NVIDIA (NVDA) trades at $223.09, up 2.54% today, with strong technical momentum as the price approaches resistance near $224. The company demonstrates exceptional fundamental strength with 55.84% net profit margins and 114.29% ROE for 2025, supported by consistent earnings beats. Recent news highlights AI leadership driving revenue growth acceleration, though some articles caution about growth sustainability given the stock's massive run-up.

Outlook remains positive with Wall Street consensus target of $325.86 implying 46% upside, though risks include peak AI spending concerns and increased competition. The stock presents a compelling growth opportunity but requires careful risk management given elevated valuations and technical overbought conditions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About Nvidia Corp

NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.

Read more on NVDA